Evaluation of Fenofibrate on Radiation-induced Skin Injury
Status:
Unknown status
Trial end date:
2020-04-13
Target enrollment:
Participant gender:
Summary
Fenofibrate is a specific ligand for PPARĪ±, which has been used for the treatment of
hypercholesterolemia, hypertriglyceridemia, diabetes and cardiovascular diseases for long
time. Fenofibrate reduces low-density lipoprotein (LDL), very low density lipoprotein (VLDL)
and triglyceride levels, while increases high-density lipoprotein (HDL) levels. PPARĪ± has
also shown antioxidant and anti-inflammatory properties. Fenofibrate confers cytoprotective
effect against myocardial ischemia-reperfusion (I/R) injury in rats by suppressing cell
apoptosis and ameliorates age-related renal injury through the activation of AMPK and SIRT1
signaling. However, the safety and effectiveness of fenofibrate on the progression of
radiation-induced skin injury remain unknown. The purpose of this study is to determine
whether topical application of fenofibrate is safe and effective for radiation-induced skin
injury.